Immune Checkpoint Receptors in AML-Leukemic Initiating Cells
NCT03449745 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 199
Last updated 2022-04-20
Summary
This project aim at deciphering immune mechanisms that allow the immunoescape of AML initiating cells.
Conditions
Sponsors & Collaborators
-
University Hospital, Bordeaux
lead OTHER
Principal Investigators
-
Edouard FORCADE · University Hospital, Bordeaux
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-05-29
- Primary Completion
- 2021-06-09
- Completion
- 2021-06-09
Countries
- France
Study Locations
More Related Trials
-
B-cell Chronic Lymphoid Malignancies Markers
NCT04952974 ·Status: UNKNOWN
-
Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL)
NCT03616782 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy
NCT01599949 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Safety and Efficacy of Betalutin and Rituximab in Patients With FL
NCT03806179 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
NCT03241173 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Relapsing or Refractory Chronic Lymphocytic Leukemia
NCT01488162 ·Status: COMPLETED
-
Study of Prognostic Factors in Adult Lymphoblastic Lymphoma
NCT03571997 ·Status: UNKNOWN
-
A Study of the Kinetics of Lymphoid Cells in Patients With Monoclonal B-cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and Healthy Volunteers
NCT01117142 ·Status: COMPLETED
-
Cardiovascular Complications of Ibrutinib Therapy
NCT05939752 ·Status: TERMINATED
-
The Study of ICP-248 in Patients With Mature B-cell Malignancies
NCT05728658 ·Status: RECRUITING ·Phase: PHASE1
-
Institut Paoli Calmettes Chronic Lymphatic Leukemia Database
NCT02869529 ·Status: RECRUITING
-
Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT02077166 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Clinico-biological Characterization and Survival of Patients With Adult T-cell Leukemia / Lymphoma (ATL) and Patients Chronically Infected With the HTLV-1 Virus (HTLV-OBS)
NCT05237245 ·Status: ACTIVE_NOT_RECRUITING
-
A Study of MabThera (Rituximab) Plus Chlorambucil in Participants With Chronic Lymphocytic Leukemia.
NCT00532129 ·Status: COMPLETED ·Phase: PHASE2
-
Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma
NCT03399513 ·Status: COMPLETED ·Phase: PHASE2
-
Alemtuzumab (CAMPATH 1H) Associated to G-CSF in Adult Patients With Refractory Acute Lymphocytic Leukemia
NCT00773149 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
NCT01833039 ·Status: APPROVED_FOR_MARKETING
-
Intensified Rituimab Prephase Before FCR in Untreated B-CLL
NCT01370772 ·Status: COMPLETED ·Phase: PHASE2
-
Tolerance and Efficacy of Subcutanous Low Doses Rituximab for CLL Consolidation Treatment
NCT01521689 ·Status: UNKNOWN ·Phase: PHASE2
-
Phase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients in Suboptimal Response After Induction Immunochemotherapy
NCT01625741 ·Status: TERMINATED ·Phase: PHASE2
-
Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma
NCT07247383 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Treatment of Localized Low Grade Lymphomas
NCT00536458 ·Status: COMPLETED ·Phase: PHASE3
-
Intensive Chemo-immunotherapy as First Line Treatment in Adult Patients With Peripheral T- Cell Lymphoma
NCT01679860 ·Status: COMPLETED ·Phase: PHASE2
-
TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma
NCT02927964 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma
NCT02494700 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2